Harvard Bioscience Stock

Harvard Bioscience EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Harvard Bioscience (HBIO) as of Aug 10, 2026 is -39.43. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -3.99 — a change of 887.44% (lower).

EV/EBIT

-39.43

YoY

887.44%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Harvard Bioscience is 2026 -39.43 . EV/EBIT (Enterprise Value to EBIT) of Harvard Bioscience was 2025 -3.99 . It decreases by 887.44% lower compared to the previous year.

The Harvard Bioscience EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
30.71 base
Jan 1, 2020
75.59 base
Jan 1, 2021
14.80 base
Jan 1, 2022
-1.76 base
Jan 1, 2023
12.06 base
Jan 1, 2024
-1.48 base
Jan 1, 2025
-4.72 base
Jan 1, 2026 (e)
-0.22 base
YEARPRICE-TO-EBIT
2026 est -0.22
2025 -4.72
2024 -1.48
2023 12.06
2022 -1.76
2021 14.80
2020 75.59
2019 30.71
2018 12.05
2017 -8.66
2016 -4.24
2015 -68.76
2014 2.78
2013 9.90
2012 32.63
2011 14.34
2010 0.87
2009 1.00
2008 0.73
2007 1.14
2006 1.40
Access this data via the Eulerpool API

Harvard Bioscience Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Harvard Bioscience's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Harvard Bioscience's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Harvard Bioscience's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Harvard Bioscience grows earnings faster than its peers.

Harvard Bioscience Stock analysis

What does Harvard Bioscience do? Harvard Bioscience Inc was founded in 1901 and is headquartered in Holliston, Massachusetts. The company is a global leader in providing instruments, technologies, and complete systems for science and research. Harvard Bioscience has established itself as one of the leading providers of products and solutions in the fields of life sciences and health research with over 100 years of industry experience. The business model of Harvard Bioscience is focused on delivering high-quality products and solutions for research needs. The company is divided into three business segments: Life Science Research Products, Preclinical Surgical Products, and Analytical Instruments. These business segments offer a variety of products, such as instruments for cell and molecular research, gene expression analysis devices, surgical instruments, and instruments for electrophysiology. The Life Science Research segment includes the business units Harvard Apparatus, Molecular Devices, and Denville Scientific. Harvard Apparatus provides instruments for cell and molecular research, physiological instruments, and animal model systems. Molecular Devices specializes in instrumental analysis methods for cell and molecular research. Denville Scientific is a leading supplier of products for cell and molecular biology, including materials for gene and protein expression and cell culture techniques. In the Preclinical Surgical Products segment, Harvard Bioscience operates with the company Hugo Sachs Elektronik. Surgical instruments and complete systems for preclinical research are offered here. These products are popular among scientists worldwide as they have been developed for conducting research with animal models. Analytical Instruments is the segment where the company operates joint ventures to develop instruments for physical, material, and life science research. In this segment, Harvard Bioscience is primarily involved in the joint venture Wasatch Microfluidics, alongside Agilent Technologies, which specializes in the development of instruments for life sciences and biotechnology. As a provider of science and research-related instruments and devices, Harvard Bioscience has a wide range of products to help researchers and scientists enhance their work more effectively. Some of the most popular products from Harvard Bioscience include tissue processing systems, neuroprotection applications, animal model holders, and electrophysiology platforms. Harvard Bioscience also offers a range of products for quality assurance and environmental protection, such as cleanroom and protection devices for material preparation and sterilization. Overall, Harvard Bioscience Inc has an excellent reputation in the industry and is one of the world's leading companies for scientific and research-related products and services. The company constantly strives to improve its products and services and adapts to the needs of its customers. It relies on innovation and continuously works to develop and implement new technologies to meet the demands of the scientific world. Harvard Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harvard Bioscience stock

EV/EBIT (Enterprise Value to EBIT) of Harvard Bioscience is -39.43 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Harvard Bioscience changed from -3.99 to -39.43, representing a 887.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Harvard Bioscience since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Harvard Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Harvard Bioscience

All Key Metrics — Harvard Bioscience